Treatment of cancer-related anemia with epoetin alfa: A review

Cancer Treatment Reviews

Volumn 30, Issue 6, 2004, Pages 563-575

  Ferrario, Erminia ^a   Ferrari, Leonardo ^a   Bidoli, Paolo ^a   De Candis, Daniela ^a   Del Vecchio, Michele ^a   De Dosso, Sara ^a   Buzzoni, Roberto ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anemia; Cancer; Epoetin alfa; Haemoglobin; Malignancy; Treatment guidelines

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN;

ANEMIA; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COGNITION; CRYSTALLOID; DOSE RESPONSE; DRUG BINDING; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; FATIGUE; FEEDBACK SYSTEM; HEMOGLOBIN DETERMINATION; HUMAN; PATHOPHYSIOLOGY; PURE RED CELL ANEMIA; QUALITY OF LIFE; RADIOSENSITIZATION; REVIEW; TISSUE OXYGENATION; TREATMENT OUTCOME;

EID: 4344627592     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.04.005     Document Type: Article

References (126)

1. Ludwig H. Barrett-Lee P.J. Gascon P. Schneider M. Van Belle S. European Cancer Anemia Survey (eECAS) defines factors surrounding anemia in thousands cancer patients Proc. Am. Soc. Clin. Oncol. 21 2002 387a (Abstract 1546)
2. Barrett-Lee P.J. Bailey N.P. O'Brien M.E. Wager E. Large scale UK audit of blood transfusion requirements and anemia in patients receiving cytotoxic chemotherapy Br. J. Cancer 82 2000 93-97
3. Waters J.S. O'Brien M.E. Ashley S. Management of anemia in patients receiving chemotherapy [letter] J. Clin. Oncol. 20 2002 601-602
4. Tas F. Eralp Y. Basaran M. et al. Anemia in oncology practice: relation to diseases and their therapies Am. J. Clin. Oncol. 25 2002 371-379
5. Casadevall N. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes Semin. Oncol. 25 Suppl 7 1998 12-18
6. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's working Party on Leukemia in Adults. Br J Cancer 1980;42:831-40
7. Coiffier B. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL Eur. J. Cancer 35 Suppl 4 1999 S331 (Abstract 1331)
8. Rizzo J.D. Lichtin A.E. Woolf S.H. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J. Clin. Oncol. 20 2002 4083-4107
9. Gregory C.J. Eaves A.C. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony response Blood 49 1977 855-864
10. Silva M. Grillot D. Benito A. Richard C. Nunez G. Fernandez-Luna J.L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2 Blood 88 1996 1576-1582
11. Sawada K. Krantz S.B. Dai C.-H. et al. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptor J. Cell Physiol. 142 1990 219-230
12. Lacombe C. Da Silva J.L. Bruneval P. et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney J. Clin. Invest. 81 1988 620-623
13. Schuster S.J. Badiavas E.V. Costa-Giomi P. Weinmann R. Erslev A.J. Caro J. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure Blood 73 1989 13-16
14. Tan C.C. Eckardt K.U. Firth J.D. et al. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia Am. J. Physiol. 263 1992 474-481
15. Lee-Huang S. Cloning and expression of human erythropoietin cDNA in Escherichia coli Proc. Natl. Acad. Sci. USA 81 1984 2708-2712
16. Liu F.K. Suggs S. Lin C.H. et al. Cloning and expression of the human erythropoietin gene Proc. Natl. Acad. Sci. USA 82 1985 7580-7584
17. Renchy M. Scoble H.A. Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin J. Biol. Chem. 262 1987 17156-17163
18. Davis J.M. Arakawa T. Strickland T.W. Yphantis D.A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells Biochemistry 26 1987 2633-2638
19. Fukuda M.N. Sasaki H. Lopez L. et al. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates Blood 73 1989 84-89
20. D'Andrea A.D. Zon L.I. Erythropoietin receptor: subunit structure and activation J. Clin. Invest. 86 1990 681-687
21. Mayeux P. Billat C. Jacquot R. The erythropoietin receptor of rat erythroid progenitor cell: characterization and affinity cross-linkage J. Biol. Chem. 262 1987 13985-13990
22. Watowich S.S. Hilton D.J. Lodish H.F. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization Mol. Cell. Biol. 14 1994 3535-3549
23. Witthuhn B. Quelle F.W. Silvennoinen O. et al. JAK2 associates with the erythropoietin receptor and its tyrosine phosphorylated and activated following Epo stimulation Cell 74 1993 227-236
24. Jones S.S. D'Andrea A.D. Haines L.L. Wong G.G. Human erythropoietin receptor: cloning, expression, and biologic characterization Blood 76 1990 31-35
25. Maouche L. Tournamille C. Hattab C. Boffa G. Cartron J.-P. Chrétien S. Cloning of the gene encoding the human erythropoietin receptor Blood 78 1991 2557-2563
26. Noguchi C.T. Bae K.S. Chin K. Wada Y. Schechter A.N. Hankins W.D. Cloning of the human erythropoietin receptor gene Blood 78 1991 2548-2556
27. Conrad K.P. Benyo D.F. Westerhausen-Larsen A. Miles T.M. Expression of erythropoietin by the human placenta FASEB J. 10 1996 760-768
28. Fenjves E.S. Ochoa M.S. Cabrera O. et al. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors Transplantation 75 2003 1356-1360
29. Westenfelder C. Biddle D.L. Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors Kidney Int. 55 1999 808-820
30. Heeschen C. Aicher A. Lehmann R. et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization Blood 102 2003 1340-1346
31. Anagnostou A. Liu Z. Steiner M. et al. Erythropoietin receptor mRNA expression in human endothelial cells Proc. Natl. Acad. Sci. USA 91 1994 3974-3978
32. Juul S. Yachnis A.T. Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus Early Hum. Develop. 52 1998 235-249
33. Juul S.E. Yachnis A.T. Rojiani A.M. Christensen R.D. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain Pediatr. Dev. Pathol. 2 1999 148-158
34. Wu H. Lee S.H. Gao J. Liu X. Iruela-Arispe M.L. Inactivation of erythropoietin leads to defects in cardiac morphogenesis Development 126 1999 3597-3605
35. Ogilvie M. Yu X. Nicolas-Metral V. et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts J. Biol. Chem. 275 2000 39754-39761
36. Sasaki R. Pleiotropic functions of erythropoietin Intern. Med. 42 2003 142-149
37. Williams D.M. Zimmers T.A. Pierce J.H. et al. The expression and role of human erythropoietin receptor in erythroid and nonerythroid cells Ann. N. Y. Acad. Sci. 718 1994 232-243
38. Lappin T.R. Maxwell A.P. Johnston P.G. EPO's alter ego: erythropoietin has multiple actions Stem Cells 20 2002 485-492
39. Koury M.J. Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells Science 248 1990 378-381
40. Spivak J.L. Pham T. Isaacs M. Hankins W.D. Erythropoietin is both a mitogen and a survival factor Blood 77 1991 1228-1233
41. Okuno Y. Takahashi T. Suzuki A. et al. Expression of the erythropoietin receptor on a human myeloma cell line Biochem. Biophys. Res. Commun. 170 1990 1128-1134
42. Kayser K. Gabius H.J. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand Zentralbl. Pathol. 138 1992 266-270
43. Komatsu N. Yamamoto M. Fujita H. et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7 Blood 82 1993 456-464
44. Yasuda Y. Fujita Y. Matsuo T. et al. Erythropoietin regulates tumour growth of human malignancies Carcinogenesis 24 2003 1021-1029
45. Ribatti D. Marzullo A. Nico B. Crivellato E. Ria R. Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma Histopathology 42 2003 246-250
46. Yoshimura A. Longmore G. Lodish H.F. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity Nature 348 1990 647-649
47. Arcasoy M.O. Jiang X. Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer Biochem. Biophys. Res. Commun. 307 2003 999-1007
48. Tucci M. Quatraro C. Dammacco F. Recent advances in understanding the pathogenesis of anemia in multiple myeloma Int. J. Hematol. 78 2003 121-125
49. Kalmanti M. Kalmanti T. Committed erythroid progentitors and erythropoietin levels in anemic children with lymphomas and tumors Pediatric. Hem. Onc. 6 1989 85-93
50. Miller C.B. Jones R.J. Piantadosi S. Abeloff M.D. Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer N. Engl. J. Med. 322 1990 1689-1692
51. Faquin W.C. Schneider T.J. Goldberg M.A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production Blood 79 1992 1987-1994
52. Taniguchi S. Dai C.H. Price J.O. Krantz S.B. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells Blood 90 1997 2244-2252
53. Welch RS, James RD, Wilkinson PM, FB. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995;1:261-266
54. Henke M. Correction of anemia-impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy Onkologie 24 2001 450-454
55. Moez B. Raudell T. A modelling study of feed forward activation in human erythrocyte glycolysis ACR Acad. Sci. III 324 2001 185-199
56. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue Semin. Oncol. 25 Suppl 7 1998 43-46
57. Cella D. The functional assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue Semin. Hematol. 34 Suppl 2 1997 13-19
58. Vogelzang NJ, Breitbart W, Cella D, et al., for The Fatigue Coalition. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997;34 (Suppl 2):4-12
59. Curt G.A. Breitbart W. Cella D. Groopman J.E. Horning S.J. Itri L.M. et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition Oncologist 5 2000 353-360
60. Carelle N. Piotto E. Bellanger A. Germanaud J. Thuillier A. Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy Cancer 95 2002 155-163
61. Simon A.M. Zittoun R. Fatigue in cancer patients Curr. Opin. Oncol. 11 1999 244-249
62. Sminia P. Acker H. Eikesdal H.P. Kaaijk P. Enger P. Slotman B. et al. Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma Anticancer Res. 23 2003 1461-1466
63. Koukourakis M.I. Giatromanolaki A. Sivridis E. Simopoulos K. Pastorek J. Wykoff C.C. et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy Clin. Cancer Res. 7 2001 3399-3403
64. Schouwink H. Oppelaar H. Rueve Kamp M. van der Valk M. Hart G. Rijken P. et al. Oxygen depletion during and after mtHPC-mediated photodynamic therapy in RIF1 and HMESO 1 tumors Rad. Res. 159 2003 190-198
65. Denko N.C. Fontana L.A. Hudson K.M. Sutphn P.D. Rychaudhuri S. Altmon R. Investigating hypoxia tumor physiology through gene expression pattern Oncogene 22 2003 5907-5914
66. Laderoute K.R. Alarcon R.M. Brody M.D. Calaoagan J.M. Chen E.Y. Knapp A.M. et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor Clin. Cancer Res. 6 2000 2941-2950
67. Sevelda P. Gnant M.F. Lainz K.H. Influence of anemia on local relapse free furvival (LRFS) of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy: an analysis of the Austrian Breast Cancer Study Group Proc. Am. Soc. Clin. Oncol. 21 2002 65a (Abstract 257)
68. Dunphy E.P. Petersen I.A. Cox R.S. Bagshaw M.A. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate Int. J. Radiat. Oncol. Biol. Phys. 16 1989 1173-1178
69. Jatzko G.R. Lisborg P.H. Denk H. Klimpfinger M. Stettner H.M. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan Cancer 76 1995 1302-1312
70. Pollack A. Zagars G.K. Dinney C.P. Swanson D.A. von Eschenbach A.C. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients Cancer 74 1994 2819-2827
71. Obermair A. Cheuk R. Horwood K. Janda M. Bachtiary B. Schwanzellberger B. et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results Cancer 92 2001 903-908
72. Glaser C.M. Millesi W. Kornek G.V. Lang S. Schüll B. Watzinger F. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int. J. Radiat. Oncol. Biol. Phys. 50 2001 705-715
73. Fein D.A. Lee W.R. Hanlon A.L. et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx J. Clin. Oncol. 13 1995 2077-2083
74. Obermair A. Handisurya A. Kaider A. Sevelda P. Kolbl H. Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review Cancer 83 1998 726-731
75. Marinaccio M. Mele E. DeMarino E. Pansini N. Pretreatment hemoglobin as a prognostic factor in epithelial ovarian cancer Proc. Am. Soc. Clin. Oncol. 21 2002 216a (Abstract 863)
76. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage a chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990;76:45-57
77. Solignac M, European Hematology Association. Epidemiological data on anemia during malignant affections. Press Med 2003;32:1368-1370
78. Grogan M. Thomas G.M. Melamed I. Wong F.L. Pearcey R.G. Joseph P.K. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix Cancer 86 1999 1528-1536
79. Lee W.R. Berkey B. Marcial V. et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27 Int. J. Radiat. Oncol. Biol. Phys. 42 1998 1069-1075
80. Wagner W. Hermann R. Hartlapp J. Esser E. Christoph B. Muller M.K. et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery Strahlenther. Onkol. 176 2000 73-80
81. Walker R.H. Special reports: transfusion risks Am. J. Clin. Pathol. 88 1987 374-378
82. National Comprehensive Cancer Network. Practice guidelines in oncology. Cancer and treatment-related anemia: v.1.2003. National Comprehensive Cancer Network, Inc.; 2003
83. Osterborg A. Brandberg Y. Molostova G. Iosava K. Abdulkadyrov K. Hedenus M. et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies J. Clin. Onc. 20 2002 2486-2494
84. Smith R.E. Tchekmedyian N.S. Chan D. Meza L.A. Northfelt D.W. Patel R. et al. A dose and schedule-finding study of darbepoetin alpha for the treatment of chronic anemia of cancer Br. J. Cancer 88 2003 1851-1858
85. Ludwig H. Fritz E. Kotzmann H. Hocker P. Gisslinger H. Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma N. Engl. J. Med. 322 1990 1693-1699
86. Platanias L.C. Miller C.B. Mick R. et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients J. Clin. Oncol. 9 1991 2021-2026
87. Abels R. Erythropoietin for anaemia in cancer patients Eur. J. Cancer 29A Suppl 2 1993 S2-S8
88. Leitgeb C. Pecherstorfer M. Fritz E. Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin Cancer 73 1994 2535-2542
89. Ludwig H. Sundal E. Pecherstorfer M. et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy Cancer 76 1995 2319-2329
90. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234
91. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425
92. Shasha D. George M.J. Harrison L.B. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy Blood 96 2000 434a (Abstract 916-II)
93. Gabrilove J.L. Cleeland C.S. Livingston R.B. Sarokhan B. Winer E. Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J. Clin. Oncol. 19 2001 2875-2882
94. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874
95. Turner R. Anglin P. Burkes R. et al. Canadian Cancer and Anemia Guidelines Development Group. Epoetin alfa in cancer patients: evidence-based guidelines J. Pain Symptom Manag. 22 2001 954-965
96. Cheung W. Minton N. Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly Eur. J. Clin. Pharmacol. 57 2001 411-418
97. Fallowfield L. Gagnon D. Zagari M. et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of opoetin alfa in patients receiving nonplatinum chemotherapy Br. J. Cancer 87 2002 1341-1353
98. Marti H.H. Gassmann M. Wenger R.H. et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain Kidney Int. 51 1997 416-418
99. Cerami A. Brines M.L. Ghezzi P. Cerami C.J. Effects of epoetin alfa on the central nervous system Semin. Oncol. 28 Suppl 8 2001 66-70
100. Buemi M. Cavallaro E. Floccari F. et al. The pleiotropic effects of erythropoietin in the central nervous system J. Neuropathol. Exp. Neurol. 62 2003 228-236
101. Chong Z.Z. Kang J.Q. Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin J. Cereb. Blood Flow Metab. 23 2003 320-330
102. Chong Z.Z. Kang J.Q. Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells Curr. Drug Targets Cardiovasc. Haematol. Disord. 3 2003 141-154
103. Chong Z.Z. Kang J.Q. Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways Br. J. Pharmacol. 138 2003 1107-1118
104. O'Shaughnessy J.A. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy Clin. Breast Cancer 3 Suppl 3 2002 S116-S120
105. Senzer N. Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation Semin. Oncol. 29 Suppl 19 2002 47-52
106. O'Shaughnessy J. Vukelja S. Savin M. Holmes F.A. Jones M. Royall D. George M. von Hoff D. Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data Breast Cancer Res. Treat 76 2002 S138 (Abstract 550)
107. Littlewood T.J. The impact of hemoglobin levels on treatment outcomes in patients with cancer Semin. Oncol. 28 Suppl 8 2001 49-53
108. Blohmer J.U. von Minckwitz G. Paepke S. et al. Sequential adjuvant chemo-radiotherapy with vs. without erythropoeitin for patients with high-risk cervical cancer-second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study Proc. Am. Soc. Clin. Oncol. 21 2002 206a (Abstract 823)
109. Tsuda E. Kawanishi G. Ueda M. The role of carbohydrate in recombinant human erythropoietin Eur. J. Biochem. 188 1990 405-411
110. Broudy V.C. Lin N. Egrie J. et al. Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide Proc. Natl. Acad. Sci. USA 85 1988 6513-6517
111. Smith R.E. JaiyesimL I.A. Meza L.A. et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anemia of chronic disease associated with cancer Br. J. Cancer 84 Suppl 1 2001 24-30
112. Egrie J.C. Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP Br. J. Cancer 84 Suppl 1 2001 3-10
113. Glaspy J. Introduction (Darbepoetin alfa supplement) Br. J. Cancer 84 Suppl 1 2001 1-2
114. Scott S.D. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clincial studies Pharmacotherapy 22 pt 2 2002 150S-165S
115. Heatherington A.C. Schuller J. Mercer A.J. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report Br. J. Cancer 84 Suppl 1 2001 11-16
116. Glaspy J.A. Jadeja J.S. Justice G. et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anemia associated with cancer chemotherapy Br. J. Cancer 87 2002 268-276
117. Zamboni W.C. Stewart C.F. An overview of the pharmacokinetic disposition of darbepoetin alfa Pharmacotherapy 22 pt 2 2002 133S-140S
118. Casadevall N. Nataf J. Viron B. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N. Engl. J. Med. 346 2002 469-475
119. Locatelli F. Del Vecchio L. Pure red cell aplasia secondary to treatment with erythropoietin Artificial Organs 27 2003 755-758
120. Prabhakar S. Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia Clin. Nephrol. 47 1997 331-335
121. Pece R. de la Torre M. Alcázar R. Urra J.M. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia N. Engl. J. Med. 335 1996 523-524
122. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Management of anemia in patients receiving chemotherapy [letter]. J Clin Oncol 2002;20:602-603
123. Finch C. Erythropoiesis, Erythropoietin, and Iron Blood 60 1982 1241-1246
124. Cleeland C. Demetri G. Glaspy J. et al. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis Proc. Am. Soc. Clin. Oncol. 18 1999 574a (Abstract 2215)
125. Nortier J.W.R. Marginal analysis to identify optimal hemoglobin levels to maximize quality of life improvement in anaemic cancer patients receiving epoetin alfa Ann. Oncol. 11 Suppl 4 2000 145 (Abstract 666O)
126. Crawford J. Cella D. Cleeland C.S. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888-895